Emcure Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,815 Cr | 3,817 Cr | 1,963 Cr | 2,116 Cr | 2,101 Cr | 2,270 Cr | 2,363 Cr | 2,470 Cr |
| Operating expenses (approx.) | 1,455 Cr | 3,041 Cr | 1,604 Cr | 1,720 Cr | 1,684 Cr | 1,791 Cr | 1,907 Cr | 1,976 Cr |
| EBITDA | 360 Cr | 776 Cr | 359 Cr | 396 Cr | 417 Cr | 479 Cr | 456 Cr | 494 Cr |
| OPM % | 19.8% | 20.3% | 18.3% | 18.7% | 19.9% | 21.1% | 19.3% | 20.0% |
| Other income | 23 Cr | 59 Cr | 4 Cr | 4 Cr | 4 Cr | 3 Cr | 2 Cr | 4 Cr |
| Interest | 59 Cr | 105 Cr | 32 Cr | 39 Cr | 27 Cr | 33 Cr | 38 Cr | 46 Cr |
| Depreciation | 94 Cr | 190 Cr | 97 Cr | 97 Cr | 99 Cr | 105 Cr | 105 Cr | 106 Cr |
| Profit before tax | 207 Cr | 481 Cr | 230 Cr | 261 Cr | 291 Cr | 341 Cr | 314 Cr | 341 Cr |
| Tax % | 26.4% | 26.3% | 32.1% | 24.3% | 26.1% | 26.4% | 26.3% | 28.6% |
| Net profit | 153 Cr | 354 Cr | 156 Cr | 197 Cr | 215 Cr | 251 Cr | 231 Cr | 244 Cr |
| EPS (₹) | ₹7.95 | ₹18.33 | ₹8.12 | ₹9.97 | ₹10.92 | ₹12.85 | ₹12.16 | ₹12.84 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 7,896 Cr | 9,204 Cr | Sign in for TTM |
| Operating expenses (approx.) | 6,365 Cr | 7,358 Cr | Sign in for TTM |
| EBITDA | 1,531 Cr | 1,846 Cr | Sign in for TTM |
| OPM % | 19.4% | 20.1% | Sign in for TTM |
| Other income | 67 Cr | 13 Cr | Sign in for TTM |
| Interest | 176 Cr | 144 Cr | Sign in for TTM |
| Depreciation | 384 Cr | 415 Cr | Sign in for TTM |
| Profit before tax | 971 Cr | 1,287 Cr | Sign in for TTM |
| Tax % | 27.2% | 26.9% | Sign in for TTM |
| Net profit | 707 Cr | 941 Cr | Sign in for TTM |
| EPS (₹) | ₹36.43 | ₹48.77 | Sign in for TTM |
| Dividend payout % | 0.0% | 6.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 189 Cr | 190 Cr |
| Reserves | 4,257 Cr | 4,760 Cr |
| Borrowings | 542 Cr | 952 Cr |
| Other liabilities | 3,049 Cr | 3,684 Cr |
| Total liabilities | 8,233 Cr | 9,612 Cr |
| Fixed assets (net) | 1,954 Cr | 1,960 Cr |
| CWIP | 124 Cr | 172 Cr |
| Investments | 95 Cr | 20 Cr |
| Other assets | 4,650 Cr | 5,709 Cr |
| Total assets | 8,233 Cr | 9,612 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | 852 Cr | 944 Cr |
| Cash from investing | -94 Cr | -1,193 Cr |
| Cash from financing | -814 Cr | 343 Cr |
| Net cash flow | -58 Cr | 112 Cr |
| Free cash flow (OCF − Capex) | 630 Cr | 583 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 22.1% | 24.1% |
| ROE % | 14.7% | 18.6% |
| Debtor days | — | — |
| Inventory days | 461 | 516 |
| Days payable | — | — |
| Cash conversion cycle | 461 | 516 |
| Debt / equity | 0.12 | 0.19 |
| Current ratio | 1.74 | 1.46 |
| Net debt / EBITDA | 0.25 | 0.44 |
Compare with peers
Loading peers…